A new study, which appeared in JAMA OphthalmologyTrusted Source earlier this week, identified a potential link between the diabetes and weight loss drug, semaglutide and a rare eye disease that causes blindness.
The condition, called nonarteritic anterior ischemic optic neuropathy (NAION), affects around 2.3 people per 100,000Trusted Source people in the United States.
The new study finds that people with diabetes who were prescribed semaglutide - which is marketed as Ozempic and Wegovy, among other names - were more than four times more likely to develop NAION compared with people with diabetes on other medications.
#ozempic #semaglutide #wegovy #news18 #cnnnews18
News18 Mobile App - onelink.to/des...